Outcome of chronic delta hepatitis in Italy: A long-term cohort study

Niro, Grazia; Smedile, Antonina; Ippolito, A.; Ciancio, Alessia; Fontana, R.; Olivero, Antonella; Valvano, Maria Rosa; Abate, Maria Lorena; Gioffreda, Domenica; Caviglia, Gian Paolo; Rizzetto, Mario; Andriulli, Angelo

doi:10.1016/j.jhep.2010.06.008

Cited by 130 publications

(131 citation statements)

References 24 publications

(24 reference statements)

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Particularly, African HDV genotypes (i.e., HDV-1 and HDV-5 to -8) are poorly quantified by almost all available assays and are either undetected or dramatically underestimated (11). These different genotypes originally had a specific geographic distribution; however, due to ancient or recent migrations of populations, this genetic variability is now encountered in different countries worldwide (9)(10)(11)(17)(18)(19)(20)(21)(22)(23)(24)(25). In this respect, France, where genotypes HDV-5 to -8 representing 20% of spreading strains were characterized, is an outstanding example (26,27).…”

Section: Discussionmentioning

confidence: 99%

Performance Characteristics of a New Consensus Commercial Kit for Hepatitis D Virus RNA Viral Load Quantification

et al. 2017

View full text Add to dashboard Cite

Hepatitis D virus (HDV) is responsible for fulminant hepatitis and liver failure and accelerates evolution toward cirrhosis and hepatocellular carcinoma in hepatitis B virus (HBV)-infected patients. To date, treatment relies upon long-term administration of pegylated alpha-interferon with a sustained virological response in 30% of the patients. Very recently, new, promising anti-HDV therapies have been developed and are already being used in clinical trials. HDV RNA viral load (HDVL) monitoring must be an integral part of the management of the infected patients. However, HDV genus is characterized by a high genetic variability into eight genotypes (HDV-1 to -8), and most available in-house or commercial assays are useful for only a limited subset of genotypes. Results of a comparison of the performance of a new kit for HDVL quantification with the consensus in-house assay of the French National Reference Laboratory for HDV developed in 2005 are reported here. A total of 611 clinical samples of all HDV genotypes with various HDVL values, including several consecutive samples over several years from 36 patients, were studied. A specificity, sensitivity, and reproducibility evaluation was conducted using HDV-positive clinical samples, hepatitis A, B, C and E (HAV, HBV, HCV, and HEV, respectively) and HIV mono-infected samples, and the WHO HDV RNA international standard. Overall results were strictly comparable between the two assays (median difference, 0.07 log IU/ml), with high diagnosis precision and capacity. In summary, this new kit showed high performance in detection/quantification of HDVL, regardless of the genotype of the infecting strain used, and seems to be a suitable tool for patient management.

show abstract

Section: Discussionmentioning

confidence: 99%

Performance Characteristics of a New Consensus Commercial Kit for Hepatitis D Virus RNA Viral Load Quantification

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Also a spontaneously HDV clearance might appear with spontaneously seroconversion to anti-HBs (0.25% annual rate). Nevertheless, therapy is needed in delta hepatitis, because HDV replication is an independent predictor of mortality [65] and lack of treatment is a predictor of an unfavourable outcome [53] . Even 8/35 patients with an SVR developed a HCC in long-term [65] , especially elderly are at a specific risk [66] .…”

Section: Main Results (S)mentioning

confidence: 99%

“…Once a stage of liver cirrhosis has developed, the viral clearance will have limited influence on the further course of liver disease. Half of patients who develop cirrhosis later will progress to liver failure [53] . To cure patients, long-term IFN treatment is required for undetectable HDV RNA and further treatment is required for HBsAg loss [67] .…”

Section: Main Results (S)mentioning

confidence: 99%

“…Because of different patterns in replication of HDV and HBV (active HDV/inactive HBV 70%, active HDV and HBV 23%, inactive HDV/active HBV 4%, both inactive 3%) [53] which vary over time a close treatment surveillance and an individually adopted therapy is likely to be essential. Possibly, patients with a high HBV replication might benefit from a therapy with nucleoside/nucleotide …”

Section: Treatment Of Delta Hepatitismentioning

confidence: 99%

See 1 more Smart Citation

Molecular and clinical aspects of hepatitis D virus infections

Dastgerdi

Herbers²,

Tacke³

2012

WJV

View full text Add to dashboard Cite

“…Persistent HDV replication leads to cirrhosis and hepatocellular carcinoma at annual rates equal to 4% and 2.8%, respectively, therefore antiviral therapy is indicated in these patients with high viral load [59]. Niro et al revealed that lack of antiviral therapy, cirrhosis at presentation and male gender were correlated with poor prognosis in patients from Italy with chronic HDV infection for a mean of 9.6 ± 7.7 years of follow-up [60].…”

Section: Clinical Featuresmentioning

confidence: 99%